Skip to main content

Advertisement

SpringerLink
Log in

Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX®) therapy in Germany

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate treatment outcomes and resource consumption of patients with neurogenic detrusor overactivity (NDO) before and after botulinum toxin A (Botox®) therapy in Germany.

Methods

In a multi-center, cross-sectional, retrospective cohort study, data of patients with NDO 12 months before and after the first Botox® therapy were analyzed.

Results

214 patients (mean age 38 ± 14.8 years, 145 male, 69 female) with NDO due to spinal cord injury (81%); myelomeningocele (14%), or Multiple Sclerosis (5%) from seven hospitals were included. Mean interval between treatments was 8 months. Following treatment, mean maximum detrusor pressure, maximum cystometric capacity and detrusor compliance improved significantly. Prior to Botox® therapy, 68% reported urinary tract infections (UTI), 63% had incontinence episodes, and 58% used incontinence aids. These numbers decreased significantly (p < 0.05) after treatment to 28, 33, and 28%, respectively. In patients using incontinence aids, mean costs per patient decreased from €2 to €1 per day, whereas the mean cost of drugs to treat UTIs per patient decreased from €163 to €80 per year, respectively.

Conclusion

This is the first study demonstrating the clinical usefulness of Botox® therapy in clinical practice. Successful treatment resulted in lower costs for NDO associated morbidity due to less need for incontinence aids and UTI medication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Webb DR, Fitzpatrick JM, O′Flynn JD (1984) A 15-year follow-up of 406 consecutive spinal cord injuries. Br J Urol 56:614–617

    Article  CAS  PubMed  Google Scholar 

  2. Gerridzen RG, Thijssen AM, Dehoux E (1992) Risk factors for upper tract deterioration in chronic spinal cord injured patients. J Urol 147:416–418

    CAS  PubMed  Google Scholar 

  3. Bruschini H, Almeida FG, Srougi M (2006) Upper and lower urinary tract evaluation of 104 patients with myelomeningocele without adequate urological management. World J Urol 24:224–228

    Article  PubMed  Google Scholar 

  4. DasGupta R, Fowler CJ (2003) Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs 63:153–166

    Article  CAS  PubMed  Google Scholar 

  5. Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD (2006) Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 25:441–445

    Article  CAS  PubMed  Google Scholar 

  6. Groah SL, Weitzenkamp DA, Lammertse DP, Whiteneck GG, Lezotte DC, Hamman RF (2002) Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Arch Phys Med Rehabil 83:346–351

    Article  PubMed  Google Scholar 

  7. Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum—a toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692–697

    Article  CAS  PubMed  Google Scholar 

  8. Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaet K, Plante P, Perrouin-Verbe B, Kumar C, Fraczek S, Brin MF, Botox Detrusor Hyperreflexia Study Team (2005) Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174:196–200

    Article  CAS  PubMed  Google Scholar 

  9. Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, Karsenty G, Schulte-Baukloh H, Schurch B, Wyndaele JJ (2008) Recommendations on the use of Botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol [Epub ahead of print]

  10. Kuo HC (2006) Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology 67:232–236

    Article  PubMed  Google Scholar 

  11. Kalsi V, Popat RB, Apostolidis A, Kavia R, Odeyemi IA, Dakin HA, Warner J, Elneil S, Fowler CJ, Dasgupta P (2006) Cost-consequence analysis evaluating the use of Botulinum neurotoxin—a in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 49:519–527

    Article  CAS  PubMed  Google Scholar 

  12. Stöhrer M, Blok B, Castro-Diaz D, Chartier-Kastler E, Del Popolo G, Kramer G, Pannek J, Radziszewski P, Wyndaele JJ (2009) EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol [Epub ahead of print]

  13. Rote Liste (2006) Rote Liste Service GmbH. Frankfurt/Main, Germany

  14. Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, Burgdörfer H, Göcking K, Madersbacher H, Schumacher S, Richter R, von Tobel J, Schurch B (2004) European experience of 200 cases treated with botulinum—a toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510–515

    Article  CAS  PubMed  Google Scholar 

  15. Sievert KD, Bremer J, Burgdörfer H, Domurath B, Hampel C, Kutzenberger J, Seif C, Stöhrer M, Wefer B, Pannek J (2007) Botulinumtoxin in der Therapie der neurogenen Detrusorhyperaktivität. Konsensuspapier zum Einsatz bei einer neurogenen Blasenfunktionsstörung. Urologe A 46:293–296

    Article  PubMed  Google Scholar 

  16. Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M (2004) Intravesical resiniferatoxin versus botulinum—a toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 172:240–243

    Article  CAS  PubMed  Google Scholar 

  17. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P (2005) A comparison between the response of patients with idiopathic detrusor overactivity and nerogenic detrusor overactivity to the first intradetrusor injection of botulinum—a toxin. J Urol 174:984–989

    Article  CAS  PubMed  Google Scholar 

  18. Schulte-Baukloh H, Weiss C, Stolze T, Herholz J, Stürzebecher B, Miller K, Knispel HH (2005) Botulinum—a toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 48:984–990

    Article  PubMed  Google Scholar 

  19. Hinkel A, Finke W, Bötel U, Gatermann SG, Pannek J (2004) Increasing resistance against antibiotics in bacteria isolated from the lower urinary tract of an outpatient population of spinal cord injury patients. Urol Int 73:143–148

    Article  CAS  PubMed  Google Scholar 

  20. Gamè X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudiè I, De Boissezon X, Malavaud B, Marque P, Rischmann P (2008) Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 53:613–618

    Article  PubMed  Google Scholar 

  21. Wu JM, Siddiqui NY, Amundsen CL, Myers ER, Havrilesky LJ, Visco AG (2009) Cost-effectiveness of botulinum toxin A versus anticholinergic medications for idiopathic urge incontinence. J Urol 181:2181–2186

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The study was financially supported by Pharm Allergan, Ettlingen, Germany.

Conflict of interest statement

There is no conflict of interest.

Author information

Authors and Affiliations

  1. Klinik für Urologie und Kinderurologie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany

    Björn Wefer & Christoph Seif

  2. MERG, Medical Economics Research Group/IMS Health, Munich, Germany

    Birgit Ehlken & Karin Berger

  3. Neurologisches Rehabilitationszentrum Greifswald GmbH, Greifswald, Germany

    Jörn Bremer

  4. Neuro-urologische Abteilung, BG-Unfallkrankenhaus Hamburg, Hamburg, Germany

    Harald Burgdörfer

  5. Klinik für Neuro-Urologie, Werner-Wicker-Klinik, Bad Wildungen, Germany

    Burkhard Domurath & Johannes Kutzenberger

  6. Urologische Klinik und Poliklinik der Johannes-Gutenberg-Universität, Mainz, Germany

    Christian Hampel

  7. Urologische Klinik, Universitätsklinikum Tübingen, Tübingen, Germany

    Karl D. Sievert

  8. Schwerpunkt Neuro-Urologie, Marienhospital Herne, Universitätsklinik, Herne, Germany

    Jürgen Pannek

  9. Chefarzt Neuro-Urologie, Schweizer Paraplegiker-Zentrum, Guido A. Zäch Strasse 1, 6207, Nottwil, Switzerland

    Jürgen Pannek

Authors
  1. Björn Wefer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Birgit Ehlken
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jörn Bremer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Harald Burgdörfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Burkhard Domurath
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christian Hampel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Johannes Kutzenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christoph Seif
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Karl D. Sievert
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Karin Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jürgen Pannek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jürgen Pannek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wefer, B., Ehlken, B., Bremer, J. et al. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX®) therapy in Germany. World J Urol 28, 385–390 (2010). https://doi.org/10.1007/s00345-009-0466-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-009-0466-1

Keywords

Search

Navigation